Senseonics Holdings, Inc. (SENS)
SENS Stock Up as Eversense 365 CGM Wins European CE Mark Approval
Senseonics stock jumps after Eversense 365 wins CE Mark, expanding Europe access for its one-year CGM and strengthening the long-term growth outlook.
SENS Stock Up as Eversense 365 Enters AID Market With twiist System
Senseonics shares gain after Eversense 365 became the first one-year implantable CGM integrated with an automated insulin delivery system.
Senseonics: Eversense 365 Is A Game Changer For The CGM Industry
Senseonics Holdings earns a buy rating as Eversense 365 drives potential product-market fit and margin expansion. SENS's integration of Ascensia's commercial team and DTC investments is expected to boost revenue and gross margins above 50%. Q3 revenue grew 90% YoY, with a 42.8% gross margin and 55% YoY revenue growth guided for 2025.
Senseonics Holdings, Inc. (SENS) Q3 2025 Earnings Call Transcript
Senseonics Holdings, Inc. ( SENS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Matthew Miksic - Barclays Bank PLC, Research Division Joshua Jennings - TD Cowen, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Jonathan Block - Stifel, Nicolaus & Company, Incorporated, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to today's Senseonics Third Quarter 2025 Earnings Conference Call.
Senseonics Holdings (SENS) Reports Q3 Loss, Beats Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.43 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to a loss of $0.8 per share a year ago.
Senseonics Holdings (SENS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
Senseonics (SENS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Senseonics Holdings, Inc. (SENS) Eversense 365 Commercial Update Call (Transcript)
Senseonics Holdings, Inc. (NYSE:SENS ) Eversense 365 Commercial Update Conference Company Participants Tim Goodnow - President, CEO & Director Frederick Sullivan - CFO, Secretary & Treasurer Conference Call Participants Jeremy Feffer - Lifesci Advisors, LLC Brian Hansen - Ascensia Diabetes Care Us Inc. Matthew Miksic - Barclays Bank PLC, Research Division Anthony Petrone - Mizuho Securities USA LLC, Research Division Joshua Jennings - TD Cowen, Research Division Benjamin Haynor - Lake Street Capital Markets, LLC, Research Division Jayson Bedford - Raymond James & Associates, Inc., Research Division Xun Lee - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good day, everyone, and welcome to the Eversense 365 Commercial Update Call.
Here's Why Senseonics (SENS) Is a Great 'Buy the Bottom' Stock Now
Senseonics (SENS) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Senseonics Holdings, Inc. (SENS) Q2 2025 Earnings Call Transcript
Senseonics Holdings, Inc. (NYSE:SENS ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Frederick T. Sullivan - CFO, Secretary & Treasurer Mukul Jain - Chief Operating Officer Timothy T.
Senseonics Holdings (SENS) Reports Q2 Loss, Tops Revenue Estimates
Senseonics Holdings (SENS) came out with a quarterly loss of $0.02 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.03 per share a year ago.
Here's Why Senseonics (SENS) is Poised for a Turnaround After Losing 5.7% in 4 Weeks
The heavy selling pressure might have exhausted for Senseonics (SENS) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Revisiting Senseonics After 4 Years: Still A Big Investment Opportunity
I share my recent interview with Senseonics CEO, Tim Goodnow and the CFO, Rick Sullivan. Senseonics has recently introduced a 365-day Continuous Glucose Monitoring system, aiming to disrupt a market dominated by short-term CGMs from DexCom, Abbott Laboratories, and Medtronic. The next 12 months will be crucial for Senseonics as they prove their technology and decide if they continue their commercial partnership with Ascensia, change partners to go solo.
